ConductScience.org, home

Paper41420060

A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.

Shi D and 13 others. Nat Microbiol, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Papers, record 41420060. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41420060

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.
PubMed
Journal
Nat Microbiol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-05
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shi DDashuang
2Ma RRui
3Gupta RRichi
4Dickey THThayne Hhttps://orcid.org/0000-0001-5773-5372
5Patel PNPalak Nhttps://orcid.org/0000-0002-6718-8664
6Salinas NDNichole D
7Tang WKWai Kwan
8Queen AAlaysies
9Singleton MMyesha
10Delbe NNida
11Conteh SSolomon
12Lambert LELynn E
13Duffy PEPatrick Ehttps://orcid.org/0000-0002-4483-5005
14Tolia NHNiraj Hhttps://orcid.org/0000-0002-2689-1337

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Malaria VaccinesMajor topic
NanoparticlesMajor topic
Plasmodium falciparumMajor topic
Protozoan ProteinsMajor topic
Malaria, FalciparumMajor topic
MalariaMajor topic
Animals
Mice
Antibodies, Protozoan
Plasmodium vivax
Female
Disease Models, Animal
Humans
Sporozoites
Mice, Inbred BALB C
Nanovaccines

Source PubMed

Download CSV of topics

References85

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138341502Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model.NPJ Vaccines2024https://conductscience.org/library/papers/38341502PubMed
230509385Molecular mimicry and autoimmunity.J Autoimmun2018https://conductscience.org/library/papers/30509385PubMed
310652487Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development.Parasitol Today2000https://conductscience.org/library/papers/10652487PubMed
434632802Nano-carriers of COVID-19 vaccines: the main pillars of efficacy.Nanomedicine (Lond)2021https://conductscience.org/library/papers/34632802PubMed
528422178Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.Sci Rep2017https://conductscience.org/library/papers/28422178PubMed
633594061Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum.Nat Commun2021https://conductscience.org/library/papers/33594061PubMed
723144750Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.PLoS One2012https://conductscience.org/library/papers/23144750PubMed
823607541Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.Malar J2013https://conductscience.org/library/papers/23607541PubMed
912438363
A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
Infect Immun2002https://conductscience.org/library/papers/12438363PubMed
1035360887Trapping and structural characterisation of a covalent intermediate in vitamin B6 biosynthesis catalysed by the Pdx1 PLP synthase.RSC Chem Biol2022https://conductscience.org/library/papers/35360887PubMed
1117542753Virus-like particles: flexible platforms for vaccine development.Expert Rev Vaccines2007https://conductscience.org/library/papers/17542753PubMed
1223142589Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.Vaccine2012https://conductscience.org/library/papers/23142589PubMed
1323454164Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Lancet Infect Dis2013https://conductscience.org/library/papers/23454164PubMed
1430324137Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts.Sci Adv2018https://conductscience.org/library/papers/30324137PubMed
1533815393Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice.Front Immunol2021https://conductscience.org/library/papers/33815393PubMed
1633964223Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.Lancet2021https://conductscience.org/library/papers/33964223PubMed
1727647886Structural definition of the lysine swing in Arabidopsis thaliana PDX1: Intermediate channeling facilitating vitamin B6 biosynthesis.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27647886PubMed
1827825348Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.Malar J2016https://conductscience.org/library/papers/27825348PubMed
1936410329The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule.Am J Trop Med Hyg2022https://conductscience.org/library/papers/36410329PubMed
2026342424Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.Lancet Infect Dis2015https://conductscience.org/library/papers/26342424PubMed

See all 85 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42915742Protective-Antigen Scaffold Nanoparticle Vaccine Overcomes Carrier-Induced Suppression and Immunosenescence to Protect against Pseudomonas aeruginosa Pneumonia.ACS Nano2026https://conductscience.org/library/papers/42915742PubMed
42856535Protective near-germline antibodies to malaria elicited by RTS,S/AS01E vaccination in African infants.bioRxiv2026https://conductscience.org/library/papers/42856535PubMed
42476547Intelligent antigen design combined with yeast display enhances targeted immune responses.Brief Bioinform2026https://conductscience.org/library/papers/42476547PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41420060

GET https://conductscience.org/api/papers/v1/41420060/references?page=2